[ TRANSACTION RECORD ]

Novo Holdings A/S Investment in Catalent — 2024

VERIFIED VECTOR ID: 002353 · tx-328
M SOURCE NODE — FUNDER
Healthcare Denmark
$16,500,000,000
EQUITY
05/02/2024
Q DESTINATION NODE — RECIPIENT
Company United States
Amount (USD)
$16.5B
Flow Type
EQUITY
Transaction Date
05/02/2024
Primary Source
Funder Profile [ M ]
AUM 160000
HQ Location Denmark
Sector Healthcare
Recipient Profile [ Q ]
Entity Catalent
Entity Type Company
Jurisdiction United States
Intelligence Note

Novo Holdings A/S agreed to acquire Catalent for 16.5 billion dollars to expand manufacturing capacity for life-saving metabolic medicines and obesity treatments. This transaction involves taking the global CDMO private. This deal is a strategic move to secure the supply chain for world-class health therapies.